436P - Efficacy and safety of necitumumab (neci) in East Asian (EA) patients (pts) with stage IV squamous non-small-cell lung cancer (NSCLC): a subanalysi...

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Keunchil Park
Citation Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532
Authors K. Park1, E.K. Cho2, M. Bello3, M.A. Ahn4, S. Thongprasert5, E. Song6, V. Soldatenkova7, H. Depenbrock8, T. Puri9, M. Orlando10
  • 1Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 2Gachon University Gil Medical Center, Namdong-gu, Incheon/KR
  • 3St. Luke's Medical Center, 1102, Quezon City/PH
  • 4Samsung Medical Center, Kangnam-Gu, Seoul/KR
  • 5Faculty Of Medicine, Maharaj Nakorn Chiang Mai, Chiang Mai University, Chiang Mai/TH
  • 6Chonbuk National University Hospital, Deokjin-gu, Jeon Ju/KR
  • 7Statistics Oncology, Lilly Deutschland GmbH, Bad Homburg/DE
  • 8Medical Oncology, Lilly Deutschland GmbH, 61352 - , Bad Homburg/DE
  • 9Eli Lilly And Company, Haryana, Gurgaon/IN
  • 10Eli Lilly Interamerica Inc., Tronador 4890, Buenos Aire/AR

Abstract

Aim/Background

The SQUIRE trial showed that neci added to gemcitabine + cisplatin (GC) improves overall survival (OS) in advanced squamous NSCLC pts. We report results of the EA subgroup.

Variable EA Non-EA
Neci + GC GC Neci + GC GC
Efficacy, median mos (95% CI) n = 43 n = 41 n = 502 n = 507
OS 12.0 (7.3, 15.2) 12.2 (5.5, 14.7) 11.5 (10.5, 12.6) 9.8 (8.8, 11.1)
HR (95% CI)* 0.805 (0.484, 1.341) 0.839 (0.730, 0.964)
PFS 5.6 (4.7, 6.4) 5.3 (2.8, 5.6) 5.7 (5.6, 6.0) 5.5 (4.8, 5.6)
HR (95% CI)* 0.720 (0.439, 1.180) 0.862 (0.749, 0.993)
Safety, n (%) n = 41 n = 39 n = 497 n = 502
Treatment- emergent AE 41 (100) 37 (94.9) 492 (99.0) 492 (98.0)
Neci related 30 (73.2) 0 378 (76.1) 0
SAE 27 (65.9) 20 (51.3) 230 (46.3) 183 (36.5)
Neci related 1 (2.4) 0 31 (6.2) 0
Grade ≥3 36 (87.8) 25 (64.1) 352 (70.8) 308 (61.4)
Neci related 5 (12.2) 0 84 (16.9) 0
With outcome death 7 (17.1) 3 (7.7) 59 (11.9) 54 (10.8)
Neci related 0 (0) 0 2 (0.4) 0

* neci + GC/GC.

Methods

Eligible pts were chemotherapy naive, ≥18 years, had stage IV squamous NSCLC, ECOG performance status 0-2, and unknown EGFR mutation status. Pts were randomly assigned to ≤ six 3-week cycles of G (1250 mg/m2) C (75 mg/m2) ± neci (800 mg). OS (median [months], 95% CI) and progression-free survival (PFS) of pts from EA (Korea, Taiwan, Singapore, Thailand, and Philippines) and non-EA countries treated with neci + GC or GC were estimated using the Kaplan-Meier method. Hazard ratios (HR) and 95% CIs of neci + GC vs GC were estimated from stratified Cox proportional hazards models.

Results

Baseline characteristics were similar between EA groups. OS and PFS were improved in EA pts treated with neci + GC vs GC, and were similar for EA vs non-EA pts treated with neci + GC (Table). The percentages of serious adverse events (SAEs), AEs Grade ≥3, and AEs with outcome of death were higher in EA pts treated with neci + GC vs GC, and in EA vs non-EA pts treated with neci + GC (Table). The percentages of AEs causally related to neci only were similar in EA and non-EA pts (Table).

Conclusions

The efficacy of neci in EA pts with advanced squamous NSCLC was consistent with those in non-EA pts. The overall percentage of AEs with neci + GC was higher in EA pts than in non-EA pts; however, the AEs related to neci were similar.

Clinical trial identification

NCT00981058

Disclosure

K. Park: consulted/advised for Astellas, Astra-Zeneca, AVEO, and Boehringer Ingelheim. M.-J. Ahn: consulted/advised for Eli Lilly and Company. V. Soldatenkova, H. Depenbrock, T. Puri, M. Orlando: employee of Eli Lilly and Company and own shares in Eli Lilly Pty Ltd. All other authors have declared no conflicts of interest.